StemCell Therapy

A rating of 18 puts BioCardia Inc (BCDA) near the bottom of the Biotechnology industry according to InvestorsObserver. BioCardia Inc's score of 18 means it scores higher than 18% of stocks in the industry. BioCardia Inc also received an overall rating of 33, putting it above 33% of all stocks. Biotechnology is ranked 15 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 33 means the stock is more attractive than 33 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

BioCardia Inc (BCDA) stock is lower by -0.41% while the S&P 500 is higher by 0.08% as of 2:24 PM on Friday, Aug 14. BCDA has fallen -$0.01 from the previous closing price of $2.41 on volume of 71,467 shares. Over the past year the S&P 500 is up 18.56% while BCDA has fallen -49.47%. BCDA lost -$2.59 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for BioCardia Inc click here.

Read more:
Is BioCardia Inc (BCDA) a Winner in the Biotechnology Industry? - InvestorsObserver

This entry was posted on August 16, 2020 at 12:58 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |